CPT® Code 91320

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use

The CPT® Code 91320 refers to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, specifically designed to combat coronavirus disease (COVID-19). This vaccine utilizes a formulation of messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNP), which is a method that allows the mRNA to be effectively delivered into human cells. The dosage specified is 30 mcg in a volume of 0.3 mL, and it is intended for intramuscular administration. The vaccine targets the spike protein of the SARS-CoV-2 virus, which is a critical component that the virus uses to enter human cells. By introducing the mRNA that encodes this spike protein, the vaccine prompts the body’s cells to produce the spike protein, thereby training the immune system to recognize and respond to the actual virus if encountered in the future. This particular formulation is a monovalent vaccine, meaning it is designed to provide immunity against a single variant of the virus, specifically the XBB.1.5 Omicron variant. The tris-sucrose formulation included in this vaccine serves to stabilize the mRNA and maintain its efficacy during storage, allowing it to be kept at standard refrigerator temperatures. It is important to note that while this code reports the supply of the vaccine, the actual administration of the vaccine is billed separately.